Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BCLIBullishCorporate Developmentsnews

Medium materiality6/10

BrainStorm to highlight NurOwn at DUPHAT; potential Phase 3b SPA, NASDAQ uplist

Aug 24, 2026, 8:19 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The PR signals active corporate development: regulatory dialogue, potential SPA-backed trial progression, and a possible NASDAQ uplist. If these catalysts materialize (SPA progress, partnerships, uplisting), investors may reprice BCLI on improved visibility and funding prospects; risk remains that none materialize or timing shifts.

AI summary

What happened, with direct paths to the underlying reporting

BrainStorm is guiding its leadership to participate in DUPHAT 2026 in Dubai, underscoring regulatory policy collaboration and public–private partnerships. The event coincides with progress toward the Phase 3b ENDURANCE trial under FDA SPA and potential NASDAQ uplisting, signaling near-term visibility catalysts that could improve investor sentiment and fundraising prospects.

BrainStorm execs to attend DUPHAT 2026 in Dubai. Keynotes cover FDA-Abraham Accords, NIH reforms.
Pitts to moderate sessions on Translational Pharmaceutical Innovation, Pharmacists roles.
Lebovits to meet Dubai partners; ENDURANCE Phase 3b SPA with FDA pursued.
DUPHAT dates Aug 25–27, 2026; NASDAQ uplisting potential noted.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.